Yttrium-90
Updates to Article Attributes
Yttrium-90 (90Y) is a radioisotope; derived from the decay of 90Sr.
Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days5. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin B-cell lymphoma radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is 90Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radioactive yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator.
Radiosynoviorthesis
Colloidal yttrium-90 citrate is the radiopharmaceutical used in radiosynoviorthesis (RSO), the radionuclide therapy for the treatment of joint inflammation 4.
Chemical-physical characteristics
Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585
Its electronic configuration is: [Kr] 4d1 5s2
The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays in the non-radioactive isotope 90Zr.
History and etymology
Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).
-<p><strong>Yttrium-90 (<sup>90</sup>Y)</strong> is a radioisotope; derived from the decay of <sup>90</sup>Sr.</p><p>Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin B-cell lymphoma radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is <sup>90</sup>Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radioactive yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator.</p><h5>Radiosynoviorthesis </h5><p>Colloidal yttrium-90 citrate is the radiopharmaceutical used in radiosynoviorthesis (RSO), the radionuclide therapy for the treatment of joint inflammation <sup>4</sup>.</p><h5>Chemical-physical characteristics</h5><p>Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585</p><p>Its electronic configuration is: [Kr] 4d1 5s2</p><p>The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays in the non-radioactive isotope <sup>90</sup>Zr.</p><h4>History and etymology</h4><p>Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).</p>- +<p><strong>Yttrium-90 (<sup>90</sup>Y)</strong> is a radioisotope; derived from the decay of <sup>90</sup>Sr.</p><p>Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days <sup>5</sup>. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin B-cell lymphoma radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is <sup>90</sup>Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radioactive yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator.</p><h5>Radiosynoviorthesis </h5><p>Colloidal yttrium-90 citrate is the radiopharmaceutical used in radiosynoviorthesis (RSO), the radionuclide therapy for the treatment of joint inflammation <sup>4</sup>.</p><h5>Chemical-physical characteristics</h5><p>Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585</p><p>Its electronic configuration is: [Kr] 4d1 5s2</p><p>The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays in the non-radioactive isotope <sup>90</sup>Zr.</p><h4>History and etymology</h4><p>Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).</p>
References changed:
- 5. Kim S, Cohalan C, Kopek N, Enger S. A Guide to 90Y Radioembolization and Its Dosimetry. Phys Med. 2019;68:132-45. <a href="https://doi.org/10.1016/j.ejmp.2019.09.236">doi:10.1016/j.ejmp.2019.09.236</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/31785502">Pubmed</a>
Unable to process the form. Check for errors and try again.